drugset / Trial / NCT00097032
Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients
Phase 3
Completed
30 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Janssen, LP · collab
RandomizedCrossoverDouble-blind
Summary
The purpose of this study is to determine whether the sedating (causing sleepiness) effects of risperidone or quetiapine alter cognitive (person's ability to think, perceive, recognize, remember, judge, and reason) functioning in subjects with stable Bipolar I Disorder.
Timeline
- Start
- 2004-10
- Primary completion
- —
- Completion
- 2005-05
Outcome
Met primary endpoint
paper On the NCS, significantly better overall cognitive function was seen after risperidone than after quetiapine at each time point after dosing. PMID 17854242 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quetiapine | Small molecule | 100 mg | — |
| Subject | Risperidone | Other / unclassified | 2 mg | — |